

## **Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights**

BRISBANE, Calif.--(BUSINESS WIRE)--Oct. 30, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Wednesday, November 6, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2019, and recent operational highlights.

To access the live call by phone, dial (877) 497-1438 (domestic) or (262) 558-6296 (international) and enter the passcode 7842939. To access a live or recorded webcast of the call, please visit the Investor Relations section of the Aimmune Therapeutics website at [www.aimmune.com](http://www.aimmune.com). The recorded webcast will be available for approximately 30 days following the call.

### **About Aimmune Therapeutics**

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for potentially life-threatening food allergies. The Company's **C**haracterized **O**ral **D**esensitization **I**mmuno**T**herapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune's first, investigational, complex biologic product candidate, PALFORZIA™ (AR101), is being developed as a treatment to reduce the frequency and severity of adverse events following exposure to peanut. The BLA for PALFORZIA is under review by the FDA, which granted PALFORZIA Breakthrough Therapy Designation in 2015 for the desensitization of peanut-allergic patients 4 to 17 years of age. The European Medicines Agency (EMA) is reviewing Aimmune's Marketing Authorization Application (MAA) for PALFORZIA, which Aimmune submitted in June 2019. Aimmune initiated a randomized phase 2 clinical trial of its second investigational, complex biologic product, AR201, for the treatment of egg allergy in August 2019. For more information, please see [www.aimmune.com](http://www.aimmune.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191030005117/en/>

Source: Aimmune Therapeutics, Inc.

#### **Investors:**

DeDe Sheel  
(917) 834-1494  
[dsheel@aimmune.com](mailto:dsheel@aimmune.com)

#### **Media:**

Jerica Pitts  
(312) 858-3469  
[jpitts@w2ogroup.com](mailto:jpitts@w2ogroup.com)

---

<https://swkhold.investorroom.com/2019-10-30-Aimmune-Therapeutics-to-Host-Conference-Call-and-Webcast-to-Discuss-Third-Quarter-2019-Financial-Results-and-Recent-Operational-Highlights>